Treanda bendamustine: Phase II data

In the German Phase II CLL2M trial in 117 previously untreated CLL patients, Treanda plus rituximab produced an ORR of 90.9%, with 36 complete remissions and 61 partial responses, plus 10 cases of stable disease. Grade 3/4 anemia, leukopenia, neutropenia and thrombocytopenia occurred in 4.9%, 14.6%, 6.5% and 6.1% of patients, respectively. Data were presented at the American Society of Hematology meeting in New Orleans. ...